Mechanism of attenuation of leptin signaling under chronic ligand stimulation by Knobelspies, Holger et al.
RESEARCH ARTICLE Open Access
Mechanism of attenuation of leptin signaling
under chronic ligand stimulation
Holger Knobelspies, Julia Zeidler, Paul Hekerman, Simone Bamberg-Lemper, Walter Becker*
Abstract
Background: Leptin is an adipocyte-derived hormone that acts via its hypothalamic receptor (LEPRb) to regulate
energy balance. A downstream effect essential for the weight-regulatory action of leptin is the phosphorylation
and activation of the latent transcription factor STAT3 by LEPRb-associated Janus kinases (JAKs). Obesity is typically
associated with chronically elevated leptin levels and a decreased ability of LEPRb to activate intracellular signal
transduction pathways (leptin resistance). Here we have studied the roles of the intracellular tyrosine residues in
the negative feedback regulation of LEPRb-signaling under chronic leptin stimulation.
Results: Mutational analysis showed that the presence of either Tyr985 and Tyr1077 in the intracellular domain of
LEPRb was sufficient for the attenuation of STAT3 phosphorylation, whereas mutation of both tyrosines rendered
LEPRb resistant to feedback regulation. Overexpression and RNA interference-mediated downregulation of
suppressor of cytokine signaling 3 (SOCS3) revealed that both Tyr985 and Tyr1077 were capable of supporting the
negative modulatory effect of SOCS3 in reporter gene assays. In contrast, the inhibitory effect of SOCS1 was
enhanced by the presence of Tyr985 but not Tyr1077. Finally, the reduction of the STAT-phosphorylating activity of
the LEPRb complex after 2 h of leptin stimulation was not accompanied by the dephosphorylation or degradation
of LEPRb or the receptor-associated JAK molecule, but depended on Tyr985 and/or Tyr1077.
Conclusions: Both Tyr985 and Tyr1077 contribute to the negative regulation of LEPRb signaling. The inhibitory
effects of SOCS1 and SOCS3 differ in the dependence on the tyrosine residues in the intracellular domain of LEPRb.
Background
Leptin is an adipocyte-secreted hormone that acts on
hypothalamic centers in the brain to control the energy
balance of the body [1]. Leptin deficiency of humans or
rodents results in hyperphagia and morbid obesity. In
patients with genetic leptin deficiency, therapy with exo-
genous leptin effectively suppresses hyperphagia and
corrects metabolic and other abnormalities [2]. How-
ever, in most cases of obesity levels of circulating leptin
are high, implying a state of resistance to the weight-
reducing effect of leptin. Consequently, clinical trials
using recombinant leptin for the pharmacological treat-
ment of obesity yielded disappointing results [3,4]. Lep-
tin resistance in rodents can be induced by short-term
voluntary overfeeding [5], by feeding high-fat diet [6-9],
and by chronically elevated leptin levels [10-12].
Reduced leptin sensitivity is also a physiological
mechanism to allow anticipatory energy intake and sto-
rage of nutrients, e.g. during pregnancy or in hibernators
[13]. Mechanisms of leptin resistance include failure of
circulating leptin to reach its targets in the brain, inhibi-
tion of the intracellular leptin signaling cascade, endo-
plasmic reticulum stress, and antagonism of the
physiological actions of leptin downstream from the pri-
mary target cell of leptin [14-19]. Regardless of the rela-
tive contributions of these mechanisms, it is clear that
the ability of leptin to activate intracellular signaling
pathways is decreased by high chronic blood levels of
leptin [15]. However, the mechanisms underlying the
leptin-induced state of reduced leptin sensitivity are not
yet understood at the molecular level.
The leptin receptor belongs to the cytokine receptor
superfamily and exists in several splicing variants. Leptin
binding to the long leptin receptor isoform (LEPRb)
activates cytokine-like signal transduction via the Janus
kinase/signal transducer and activator of transcription
(JAK/STAT) pathway. Leptin stimulation leads to the
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activation of JAKs that are constitutively associated with
LEPRb and in turn phosphorylate tyrosine residues in
the intracellular domain of the receptor [20]. The phos-
phorylated tyrosines (pTyr) provide docking sites for
proteins with Src homology 2 (SH2) domains. pTyr985
(numbering refers to the sequence of murine LEPRb)
recruits the tyrosine phosphatase SHP2, which mediates
the activation of the RAS/RAF/ERK pathway, whereas
the STAT proteins bind to pTyr1077 (STAT5) and
pTyr1138 (STAT1, STAT3 and STAT5) (for recent
reviews see [16,17,21]). The bound STAT factors are
phosphorylated by the receptor-associated JAK kinases,
dimerize and translocate to the nucleus to control tran-
scription of specific target genes. LEPRb-induced
STAT3 activation is essential for leptin regulation of
energy balance [22,23].
Although SHP2 has tyrosine phosphatase activity, its
overexpression or knockdown only marginally alters the
levels of leptin-induced STAT3 phosphorylation [24,25].
Multiple studies support roles for two inhibitory pro-
teins, suppressor of cytokine signaling 3 (SOCS3) and
protein tyrosine phosphatase 1B (PTP1B), as negative
regulators of leptin signaling. The level of PTP1B
expression modulates LEPRb signaling in cell lines and
in vivo [26], and its upregulation by leptin implies a
function as a negative feedback regulator [27]. Numer-
ous studies have demonstrated that the upregulation of
SOCS3 by leptin contributes to the attenuation of
LEPRb signaling in vivo and in cultured cells [15,28,29].
SOCS3 suppresses cytokine signaling by inhibiting the
receptor-associated JAK kinase [30] or by targeting
bound signaling proteins for proteasomal degradation
[28,31,32]. Optimal inhibition of JAKs occurs when
SOCS3 is recruited to cytokine receptor complexes via
binding to specific phosphotyrosine motifs (pTyr759 in
gp130, pTyr985 in LEPRb, pTyr401 in the erythropoietin
receptor, pTyr800 in the IL-12Rb2 [33-37]. SOCS1 is
structurally similar to SOCS3 and is generally thought
to inhibit JAKs by direct binding to the activation loop
of the kinase, independent of receptor-tyrosine motifs
[33,34,38].
Numerous studies have implicated the intracellular
tyrosine residues of LEPRb in the negative regulation of
leptin signaling. Tyr1138 is essential for the STAT3-
dependent upregulation of the feedback inhibitor
SOCS3 in response to leptin stimulation [39-41], and
the mutation of Tyr1138 prevented the attenuation of
ERK activation during prolonged leptin stimulation [25].
Moreover, the phenotype of knock-in mice expressing a
LEPRb mutant for Tyr1138 provides evidence of
increased effects of leptin that are independent of
STAT3 [25]. No clear picture has yet emerged concern-
ing the roles of Tyr985 and Tyr1077 in the attenuation
of LEPRb signaling. Bjørbaek et al. [36] demonstrated
that SOCS3 inhibits leptin signaling via binding to
pTyr985, but the attenuation of LEPRb-induced ERK
activation was later shown to occur independently of
Tyr985 [25]. Tyr1077 was only recently established as
an in vivo-phosphorylation site of LEPRb [42] although
its possible role as recruitment site for SOCS3 has
already been suggested in an earlier study [41]. In addi-
tion to the unresolved contribution of Tyr985 and
Tyr1077 in the negative regulation of leptin signaling,
the molecular mechanisms by which SOCS3 inhibits
LEPRb under chronic stimulation remain poorly
characterized.
In the present study we analyzed the molecular
mechanisms of attenuation of leptin signaling under
conditions of continuous stimulation. In particular, we
focused on the contribution of the intracellular tyrosine
residues in LEPRb and their interaction with SOCS1
and SOCS3. We found that the presence of one of the
two proximal intracellular tyrosine residues (Tyr985 or
Tyr1077) was sufficient for the attenuation of STAT3
activation, and that either tyrosine residue can support
the suppression of LEPRb signaling by SOCS3. Finally,
we show that the receptor-associated JAK kinase has
reduced STAT-phosphorylating activity after two hours
of continuous receptor stimulation. However, the kinase
is not dephosphorylated or degraded, and the inhibition
of activity depends on the presence of Tyr985 and
Tyr1077 in LEPRb.
Results
Attenuation of leptin-induced STAT3 activation depends
on the presence of either Tyr985 or Tyr1077
To examine the role of Tyr985 and Tyr1077 in the
attenuation of LEPRb signaling during prolonged ligand
stimulation, we determined the kinetics of leptin-
induced STAT3 tyrosine phosphorylation in RINm5F
cells. We have previously established the insulinoma cell
line RINm5F as a model system to define the differential
effects of the intracellular tyrosines in LEPRb signal
transduction and their effects on gene expression
[43,44]. We used RINm5F subclones expressing wild
type (WT) LEPRb or mutant receptor construct in
which one or both of these tyrosines were mutated to
phenylalanine. The presence of Tyr1138 in the mutant
receptors allowed us to monitor STAT3 tyrosine phos-
phorylation as the principle downstream signaling event.
As shown in Figure 1, continuous treatment of
RINm5F-LEPRb-WT cells with leptin resulted in a max-
imal tyrosine phosphorylation of STAT3 from 15 - 75
min, after which the level of the phosphorylated STAT3
declined sharply but remained detectable at reduced
levels for 3 h. Mutation of neither Tyr985 nor Tyr1077
in LEPRb-FYY and LEPRb-YFY abrogated the attenua-
tion of LEPRb signaling. STAT3 activation by the
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LEPRb double mutant lacking both Tyr985 and Tyr1077
(LEPRb-FFY) did not decline during the 4-h treatment
with leptin. Similar time courses of STAT3 phosphoryla-
tion were observed in HIT-T15 cells transiently expres-
sing wild type and mutant LEPRb constructs (see
additional file 1: supplementary Figure S1).
Leptin induces expression of SOCS3 but not SOCS1 in
RINm5F cells
We determined the surface expression of LEPRb in
untreated and leptin-treated RINm5F cells to examine
whether leptin signaling was downregulated by receptor
internalization and/or degradation. After 2 h of leptin
treatment, binding assays showed only a weakly reduced
leptin binding to the cell surface, which could not
account for the reduced STAT3 phosphorylation (Figure
2A). Next we used the transcriptional inhibitor, actino-
mycin D, to reveal whether active gene expression was
required for feedback inhibition. As shown in Figure 2B,
treatment with actinomycin D prevented the decrease of
leptin-induced STAT3 phosphorylation over time. A
similar result was obtained by treatment with cyclohexi-
mide (10 μg/ml; data not shown). These observations
are consistent with the hypothesis that LEPRb signaling
in RINm5F cells is attenuated by the upregulation of
SOCS family proteins. Therefore, we examined whether
leptin induced the expression of SOCS1 and SOCS3 in
RINm5F cells. As previously observed in other cell lines
(CHO, PC12, and 32D, rat skeletal muscle cells
[39-41,45]), leptin induced a rapid upregulation of
SOCS3 mRNA levels within 1 h but did not affect the
expression of SOCS1 (Figure 3A). However, SOCS1
mRNA was upregulated in response to IL-1b or the
simultaneous application of leptin and IL-1b. We tested
this combination of cytokines because we had previously
shown that IL-1b enhanced the expression of several
leptin-induced genes in RINm5F cells [44]. In contrast
to a previous study in RINm5F cells [46], we observed
no upregulation of SOCS3 mRNA by IL-1b. Consistent
with previous reports that the transcription of the
SOCS3 gene is regulated by STAT3, Tyr1138 was suffi-
cient for the induction of SOCS3 expression in RINm5F
cells (Figure 3B). Thus, the LEPRb constructs used
throughout this study were fully capable of inducing the
expression of SOCS3.
Inhibition of LEPRb point mutants by SOCS3 and SOCS1
Next we analyzed the roles of Tyr985 and Tyr1077 in
the negative regulation of LEPRb signaling with the help
of STAT3-dependent reporter gene assays. These assays
were performed in the hepatoma cell line HepG2 to
allow for ensuing knockdown experiments with shRNA
vectors directed against human SOCS1 and SOCS3 (see
below). As shown in Figure 4A, mutation of Tyr985
(LEPRb-FYY) caused a twofold increase of leptin-
induced reporter gene activity, consistent with the
known function of this tyrosine as a docking site for
SOCS3. Significantly higher luciferase activity was
induced by the mutant receptor lacking both Tyr985
and Tyr1077 (FFY), indicating that Tyr1077 also plays a
role in the negative regulation of LEPRb®STAT3 sig-
naling. However, mutation of Tyr1077 alone did not
affect promoter activity (YFY mutant).
To determine the requirement of Tyr985 and Tyr1077
for the inhibitory effects of SOCS proteins, we studied
the effects of SOCS3 and SOCS1 overexpression on the
Figure 1 Time course of STAT3 activation by LEPRb tyrosine/
phenylalanine mutants. A, Schematic representation of the LEPRb
point mutants used in this study. The membrane-proximal box1/2
region binds the JAK family kinase and Tyr1138 (box3) mediates the
activation of STAT3. B, RINm5F cells expressing WT or mutant LEPRb
(FFY, FYY, YFY) were treated with leptin (20 ng/ml) for the times
indicated (0 min, 15 min, 45 min, 75 min, 135 min, 255 min). Total
cellular lysates were subjected to Western blot analysis and
immunodetection with the indicated antibodies. These results are
representative of 2 (YFY) or at least 3 (WT, FFY, FYY) independent
experiments.
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activation of the STAT3-dependent promoter by the
LEPRb mutants. Both SOCS proteins were expressed
from the same vector and at comparable levels (see
additional file 1: supplementary Figure S2C), allowing us
to directly compare the inhibitory potencies of SOCS1
and SOCS3 on leptin-induced promoter activation. The
expression level of the SOCS proteins was carefully
titrated to attain a submaximal degree of inhibition.
Transfection of SOCS3 expression plasmid resulted in
a dose-dependent decrease of luciferase activity induced
by wild type LEPRb in HepG2 cells (Figure 4B). Muta-
tion of Tyr985 in LEPRb-FYY reduced but did not pre-
vent the inhibitory effect of SOCS3. In contrast, LEPRb-
FFY was largely resistant to SOCS3 overexpression and
was only weakly inhibited by the highest expression
levels of SOCS3. This result provides evidence that
Figure 2 Attenuation of LEPRb signaling is not due to receptor internalization and depends on active gene expression. A, Binding of
leptin-SEAP to RINm5F cells stably expressing LEPRb was determined after cells were treated with leptin (20 ng/nl) for 2 h or were not treated
(Ctrl). Nonspecific binding was determined by incubating parallel cultures with leptin-SEAP in the presence of excess unlabeled leptin (2 μg/ml)
and was subtracted. Bound phosphatase activity was determined using a chemoluminescence-based assay. Bars represent means and S.D. values
of six independent experiments. Reduction of LEPRb surface expression after treatment with leptin was not significant (paired t-test). B, RINm5F
cells stably expressing wild type LEPRb were treated with actinomycin D (5 μg/ml) for 30 min before stimulation with leptin (20 ng/ml). The
time course of leptin-induced STAT3 phosphorylation was analyzed by Western blots of total cellular lysates with the indicated antibodies. This
results are representative of two independent experiments.
Figure 3 Induction of SOCS1 and SOCS3 mRNA by leptin and IL-1b. A, RINm5F cells stably expressing wild type LEPRb were treated with
leptin (100 ng/ml), IL-1b (50 U/ml) or a combination of both for the times indicated (1, 3, 7 or 16 h). B, RINm5F cells stably expressing the
indicated LEPRb tyrosine mutants were treated with 100 ng/ml leptin (L) or vehicle (Ø) for 1 h. Total RNA was isolated and subjected to
Northern blot analysis with cDNA probes for SOCS1, SOCS3 or ribosomal protein L4 (RPL4) as an unregulated control mRNA.
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SOCS3 inhibits LEPRb signaling not only by binding to
Tyr985 but also to Tyr1077. A similar result was
obtained in the hamster insulinoma cell line HIT-T15,
although LEPRb-FYY and LEPRb-FFY differed in their
sensitivity to SOCS3 only at higher expression levels
(see additional file 1: supplementary Figure S2A).
Overexpressed SOCS1 inhibited wild type LEPRb as
efficiently as SOCS3 (Figure 4C). Unexpectedly, SOCS1
had a significantly weaker inhibitory effect on LEPRb-
FYY than on the wild type receptor, suggesting that
SOCS1 exerts its effect partially by binding to pTyr985.
In contrast to SOCS3, SOCS1 inhibited LEPRb-FYY and
LEPRb-FFY with the same potency.
Knockdown experiments
We performed knockdown experiments to address
whether endogenous levels of SOCS3 suffice to inhibit
LEPRb signaling via binding to pTyr1077. Endogenous
SOCS3 accumulated to higher levels after stimulation of
LEPRb-FFY than LEPRb-FYY, confirming that Tyr1077
contributes to the negative regulation of the effects of
leptin on gene expression. Expression of a SOCS3-direc-
ted shRNA reduced the expression of leptin-induced
SOCS3 below the limits of detection (Figure 5A). Pro-
moter activation by wild type LEPRb was enhanced 5-
fold by knockdown of SOCS3 expression (Figure 5B),
indicating that the negative feedback through SOCS3
plays a critical role in the modulation of the leptin
response in HepG2 cells. Promoter activation by
LEPRb-FYY was also significantly enhanced by knock-
down of SOCS3, indicating that Tyr985 is not essential
for the inhibitory effect of SOCS3. In contrast, the
activity of LEPRb-FFY was not altered by the knock-
down plasmid, suggesting that Tyr1077 must be respon-
sible for the inhibitory effect of SOCS3 on LEPRb-FYY.
Knockdown of SOCS1 expression increased LEPRb-
induced promoter activity only by approximately 50%
(Figure 5C) since SOCS1 is not induced by leptin (see
above, Figure 3). Consistent with the above observation
that the effect of SOCS1 was partially dependent on
receptor tyrosine motifs, knockdown of SOCS1 did not
further enhance the activity of LEPRb-FFY. However,
the difference between the mutant receptor construct
did not reach statistical significance.
JAK2 inhibition during downregulation of LEPRb signaling
is not correlated with dephosphorylation
SOCS1 and SOCS3 harbor KIR domains that are
thought to suppress JAK kinase activity by acting as
substrate mimetics [30]. We designed an assay to deter-
mine the STAT-phosphorylating activity of the JAK
kinase in LEPRb receptor complexes. Immunoprecipi-
tated receptor complexes were incubated with recombi-
nant STAT1 in the presence of ATP, and tyrosine
phosphorylation of STAT1 was determined by Western
blot analysis with an antibody specific for pTyr701 (Fig-
ure 6A). STAT1 was used as a substrate because recom-
binant STAT3 was not commercially available at that
time, and because STAT1 is also activated by leptin in
RINm5F cells [44]. Similar to STAT3, tyrosine phos-
phorylation of the endogenous STAT1 in the lysates of
the RINm5F-(LEPRb-WT) cells was reduced to near
background levels after 2 h of leptin treatment but
remained detectable in the LEPRb-FFY expressing cells
Figure 4 Inhibitory effect of SOCS1 and SOCS3 on reporter gene induction by LEPRb point mutants. HepG2 cells were transfected with
pGL3a2M-215Luc and vectors for the indicated LEPRb point mutants along with varying amounts of expression plasmids for SOCS3 or SOCS1.
Cells were treated with leptin (100 ng/ml) for 16 h before luciferase activities were determined and normalized to b-galactosidase. A, Reporter
gene activities for the different LEPRb constructs in the absence of co-transfected pEF-SOCS expression plasmids (means ± S.D. from 6
experiments). The difference between FYY and FFY is statistically significant (Student’s t-test, P < 0.01). B and C, The graphs present the
normalized luciferase activities relative to those of cells expressing no exogenous SOCS protein (means ± S.D. from 3 experiments). The
differential response of FYY and FFY to the highest expression level of SOCS3 was statistically significant. The difference of the response of WT
and FYY to SOCS1 was significant at all expression levels (Welch’s t-test, P < 0.05).
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(Figure 6B). Surprisingly, the phosphorylation of the tyr-
osines in the activation loop of JAK2 (Tyr1007/1008)
was not reduced at this time point, and no difference in
JAK phosphorylation between WT and mutant LEPRb
was observed. However, STAT1-phosphorylating activity
of the WT LEPRb complex was markedly reduced after
2 h leptin treatment. In contrast, kinase activity
remained constant in the LEPRb-FFY complexes. This
result suggests that i) LEPRb signaling during chronic
receptor stimulation is downregulated at the level of
JAK activity, ii) kinase activity does not correlate with
the phosphorylation of the tyrosines in the activation
loop of the receptor-associated JAK kinase, and iii) the
downregulation of leptin signaling depends on the pre-
sence of Tyr985 and/or Tyr1077 in LEPRb.
Discussion
In the present study we have deciphered the roles of the
intracellular tyrosines for the attenuation of LEPRb sig-
naling, in particular for the inhibitory effects of SOCS3
and SOCS1, and provide new evidence regarding the
mechanism by which LEPRb signaling is terminated
during chronic stimulation.
Role of Tyr1077
We present a series of results documenting that
Tyr1077 has a role in the negative regulation of LEPRb:
(i) The presence of either Tyr985 or Tyr1077 in the
cytoplasmic domain of LEPRb is sufficient for the
attenuation of leptin-induced STAT3 phosphorylation
(Figure 1). (ii) LEPRb-FFY induces significantly higher
reporter gene activity in HepG2 cells than LEPRb-FYY
(Figure 3A), suggesting that Tyr1077 contributes to
negative regulation of leptin-induced gene expression. A
similar effect has been observed in the neuronal PC12
cell line [47] but neither in Hek293 cells [41] nor our
previous study of HIT-T15 insulinoma cells [43]. The
cell type specificity may be due to varying expression
levels of other signaling molecules that compete for
binding to pTyr1077, such as STAT5, SOCS2 or CIS
[43,48]. (iii) The inhibitory effect of SOCS3 was reduced
but still clearly present in the absence of Tyr985
(LEPRb-FYY), whereas the mutation of both Tyr985 and
Tyr1077 (LEPRb-FFY) rendered LEPRb largely resistant
to the inhibitory effect of SOCS3 (Figure 3B). This result
contrasts with that of Bjørbaek et al. [36], which sug-
gested that overexpressed SOCS3 failed to inhibit
STAT3-dependent reporter gene activity mediated by a
Tyr985 mutant LEPRb construct. This difference may be
attributed to the use of erythropoietin receptor-LEPRb
chimeras in that study, or more likely, to the different
cell systems used. Consistent with the results obtained
in 293 cells by Bjørbaek et al. [36], we show that SOCS3
inhibited LEPRb-FYY in HIT-T15 cells only at the high-
est levels of expression (see additional file 1: supplemen-
tary Figure S2). (iv) The knockdown experiments show
clearly that endogenous levels of SOCS3 are sufficient
for the inhibition of LEPRb®STAT3 signaling via
pTyr1077 in HepG2 cells (Figure 4B). Whereas reporter
gene activity stimulated by LEPRb-FYY was significantly
enhanced by knockdown of SOCS3, this was not the
case for the double mutant (LEPRb-FFY). Thus, the
inhibitory effect of endogenous SOCS3 is strictly depen-
dent on the presence of either Tyr985 or Tyr1077. (v)
Finally, LEPRb-FFY induced higher levels of SOCS3
than LEPRb-FYY (Figure 4A), confirming that the
enhanced STAT3 activation translates into increased
Figure 5 Effect of SOCS3 knockdown on reporter gene induction by LEPRb point mutants. A, SOCS3 expression levels. - HEPG2 cells were
transfected with the expression plasmids for the indicated LEPRb constructs, pSUPER-SOCS3 (300 ng/well) or pEF-SOCS3 (10 ng/well). Levels of
endogenous SOCS3 in leptin-treated cells (16 h, 100 ng/ml) or overexpressed FLAG-SOCS3 were determined by immunoprecipitation and
Western blot analysis with SOCS3-specific antibody. B and C, Knockdown of SOCS1 or SOCS3. The reporter gene assays were performed as in
Figure 3 except that shRNA vectors specific for SOCS1 or SOCS3 were co-transfected (300 ng/well). Columns reflect luciferase activities relative to
the activity in cells transfected with empty knockdown vector (means ± S.D., n = 3 independent experiments in B and n = 5 in C). The
difference of the responses of FYY and FFY to the knockdown of SOCS3 was significant (Student’s t-test, P < 0.05).
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expression of an endogenous gene, not just the exogen-
ous reporter construct.
Taken together, these results establish a role of
pTyr1077 in the negative regulation of the LEPRb recep-
tor complex, thus extending the prevailing view that
Tyr985 is critical for the negative feedback regulation of
leptin signaling. De Souza et al. [49] have determined
affinities of 8.3 μM and 26 μM for the binding of
SOCS3 to phosphopeptides corresponding to regions
surrounding and Tyr985 and Tyr1077 of LEPRb. Bind-
ing to pTyr1077 in LEPRb was thus somewhat weaker
than to pTyr985, much weaker than to pTyr759 in the
gp130 receptor (0.1 μM), but stronger than to the
SOCS3 binding site of the erythropoietin receptor
(pTyr425, 69 μM).
The capacity of Tyr1077 to substitute for the mutated
Tyr985 provides an explanation for the Tyr985-indepen-
dent attenuation of leptin signaling observed by Dunn et
Figure 6 Assay of JAK2 activity in LEPRb complexes. A, Outline of the method. - RINm5F cells stably expressing WT or mutant (FFY) LEPRb
were treated with leptin (20 ng/ml) for the 15 min or 120 min as indicated. LEPRb receptor complexes were immunoprecipitated (IP) with an
antibody directed against the C-terminal myc tag of LEPRb. Immunoprecipitates were incubated with recombinant STAT1 as substrate in the
presence of ATP, and phosphorylation of STAT1 was determined by Western blot analysis of the supernatant (kinase activity). B, Western blot
analysis. - Activation loop phosphorylation of JAK2 was assessed in the immunoprecipitates with a phosphospecific antibody (anti Tyr1007/1008,
PY-JAK2). Catalytic activity of receptor-bound JAK2 was determined as the phosphorylation of STAT1 on Tyr701 (PY-STAT1). LEPRb and total STAT
were detected to control for comparable levels of expression or immunoprecipitation, respectively. A control reaction that was performed in the
absence of ATP is marked by an asterisk (*). In two independent experiments, STAT1 phosphorylation by LEPRb-WT complexes was reduced by
57.3% and 42.6% after 2 h of leptin treatment, whereas the STAT1 phosphorylating activity of LEPRb-FFY complexes remained constant (103.1%
and 111.3%).
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al. [25]. Furthermore, this role for Tyr1077 may also
explain why mice homozygous for a knock-in mutation
of Tyr985 LEPRb display a relatively weak phenotype
[50], as compared to mice with the corresponding muta-
tion in the IL-6 cytokine family receptor signaling subu-
nit glycoprotein 130 (gp130). The disruption of the
negative feedback on gp130-dependent STAT signaling
causes STAT3 hyperactivation, and these mice develop
a broad spectrum of hematopoietic abnormalities,
including splenomegaly, lymphadenopathy, thrombocy-
tosis and autoimmune arthritis [51-54]. In contrast,
although homozygous LeprLeu985 mice display a pheno-
type of increased leptin sensitivity, the effect of this
mutation was only significant in females and under con-
ditions of high fat diet [50]. This mild phenotype is
likely due to the negative feedback regulation through
Tyr1077, which partially compensates for the mutation
of Tyr985.
SOCS1 inhibits LEPRb signaling
We have shown by direct comparisons that SOCS1 inhi-
bits LEPRb®STAT3 signaling as potently as SOCS3.
Furthermore, our results challenge the prevailing view
that SOCS1 inhibits JAK kinases by directly binding to
the activation loop, independent of receptor phosphotyr-
osine motifs [33,38,55]. Even at low expression levels,
SOCS1 inhibited wild type LEPRb more efficiently than
LEPRb-FYY and LEPRb-FFY (Figure 4C). This is not the
first report that SOCS1 requires binding to a receptor
chain tyrosine for its inhibitory effect. The inhibition of
interferon-g signaling by SOCS1 has been shown to
depend strictly on the presence of Tyr441 in the inter-
feron-g receptor subunit 1 [56]. A similar observation
has been reported for the G-CSF receptor in which
Tyr729 is required for the inhibitory action of both
SOCS1 and SOCS3 [57]. This result was challenged by a
later study in which only the inhibitory effect of SOCS3
but not SOCS1 depended on the presence of Tyr729
[58]. However, these seemingly conflicting data may be
attributed to the different cell types used and/or to vary-
ing levels of SOCS overexpression. Because high levels
of protein expression can conceal potential differences
in the avidity of binding sites, we took care to study the
effects of the SOCS proteins on LEPRb at expression
levels that cause only partial inhibition of reporter gene
activity. We conclude from our data that the inhibitory
effect of SOCS1 on LEPRb in HepG2 cells is strongly
enhanced by the presence of the Tyr985 phosphotyro-
sine motif. SOCS1 is less dependent than SOCS3 on
this binding site (Figure 4), consistent with the higher
affinity of JAK2 for the SOCS1 vs. SOCS3 SH2 domain
[35]. Notably, the requirement of docking sites for the
actions of SOCS1 and SOCS3 may differ between differ-
ent cytokine receptors. A recent study has revealed that
the feedback inhibition of the oncostatin M receptor by
SOCS3 was independent of phosphotyrosine motifs in
the receptor chain, whereas the same levels SOCS3 did
not inhibit gp130 in the absence of Tyr759 [59]. Hence,
differences in requirement of recruitment sites, in addi-
tion to differences in the induction by various cytokines
and different kinetics of induction [60], critically deter-
mine the modulatory effects of SOCS1 and SOCS3 on
cytokine receptor signaling. Further analyses will be
necessary to characterize the binding of SOCS1 to
pTyr985 and reveal the physiological consequence of
this interaction for the function of LEPRb.
The inhibitory effect of SOCS1 on LEPRb signaling
has not previously been analyzed as a mechanism of lep-
tin resistance, because leptin does not induce expression
of SOCS1 ([39], Figure 3 of the present study). However,
SOCS1 may inhibit LEPRb as a consequence of crosstalk
between signaling pathways (e.g. IL-1b or IFNg) rather
than as a feedback mechanism. Interestingly, SOCS1 has
been reported to be upregulated in adipose tissue in two
different models of obesity associated with leptin resis-
tance [61]. In the arcuate nucleus, steroid hormone
dependent upregulation of SOCS1 contributes to prolac-
tin resistance in late pregnancy [62], and may also con-
tribute to the reduced leptin responsiveness in
pregnancy. It remains to be determined whether upregu-
lation of SOCS1 by other pathways plays a part in cen-
tral or peripheral leptin resistance.
JAK inhibition
Cytokine receptors are subject to downregulation by a
variety of mechanisms, such as internalization, depho-
sphorylation and degradation. Here we have focused on
the mechanism by which STAT activation through
LEPRb is quickly attenuated within two hours of contin-
uous leptin stimulation. As previously observed in CHO
cells [39], LEPRb surface expression was not signifi-
cantly reduced after two hours (Figure 2A). This result
is consistent with the previous observation that presence
or the absence of leptin did not alter the internalization
rate of LEPRb [63]. Therefore, we asked whether the
STAT phosphorylating activity of the receptor complex
was altered after two hours of leptin treatment. Indeed,
we observed markedly reduced activity of the JAK
kinase associated with wild type LEPRb but not LEPRb-
FFY. Our experimental approach allowed us to exclude
several other potential mechanisms of receptor inactiva-
tion. (i) The receptor-associated JAK molecules were
not dephosphorylated at this time point, excluding the
possibility that tyrosine phosphatases, in particular
PTP1B or SHP-2, are responsible for the fast inactiva-
tion of the JAK kinases. This result implies that the
phosphorylation state of the JAKs is not a reliable mea-
sure of the catalytic activity, at least when the inactiva-
tion kinetics is concerned. (ii) The fact that the amounts
of the receptor chain and the JAK kinase were not
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reduced after 2 h of leptin treatment suggests that the
attenuation of LEPRb signaling is not a consequence of
SOCS- triggered degradation of the receptor or the
associated kinase [32,55]. Moreover, termination of
STAT phosphorylation is not caused by the dissociation
of the JAK molecules from the receptor complex, a
mechanism previously described for the receptors for
erythropoietin, thrombopoietin and growth hormone
[64]. (iii) The direct measurement of the reduced JAK
activity in the isolated receptor complex excludes the
possibility that the decrease of STAT tyrosine phosphor-
ylation is exclusively determined by the rate of STAT
dephosphorylation (e.g. by TC-PTP [65]). The depho-
sphorylation of STAT1 and STAT3 must occur rapidly
to allow for the fast termination of leptin signaling, but
the downregulation of JAK activity is required to achieve
the net reduction of STAT tyrosine phosphorylation and
activation.
Conclusions
Taken together, we conclude from the available evidence
and our present results that the first step in the attenua-
tion of LEPRb®STAT3 signaling in cells chronically sti-
mulated by leptin occurs through the fast upregulation
of the negative feedback regulator SOCS3. SOCS3 is
recruited to either pTyr985 or pTyr1077 in the receptor
chain and inhibits the receptor-associated JAK mole-
cules by direct interaction of its kinase inhibitory region
(KIR) with the activation loop of the kinase. The next
step is putatively the dephosphorylation of the JAK
molecules and/or the receptor, which is a fast event in
some cell systems (e.g. Hek293 [25]) but was separable
from the initial inhibition of JAK activity in our experi-
ments. Other mechanisms of negative regulation may
play a role at later stages and contribute to the state of
reduced leptin responsiveness induced by chronic leptin
stimulation.
Methods
Cytokines and antibodies
Recombinant murine leptin was purchased from Pepro-
Tech (London, UK) and recombinant human IL-1b
from Roche Molecular Biochemicals (Mannheim, Ger-
many). The following primary antibodies were used:
polyclonal rabbit antibodies directed against p(Tyr701)-
STAT1, p(Tyr705)-STAT3, STAT1, STAT3 (Cell Signal-
ing Technology, Beverly, MA), p(Tyr1007/Tyr1008)-
JAK2 (BioSource Technologies, Camarillo, CA) and
SOCS3 (H-103, Santa Cruz Biotechnology, Santa Cruz,
CA); goat anti mouse LEPR from R&D Systems (Min-
neapolis, MN), mouse monoclonal FLAG-M2 from
Sigma-Aldrich (Taufkirchen, Germany), secondary
horseradish peroxidase-labeled antibodies from Pierce
Chemical Co. (Rockford, IL), and Dianova (Hamburg,
Germany). Detection of immunoprecipitated SOCS3 was
performed with biotinylated SOCS3-specific antibodies
(M20, Santa Cruz Biotechnology) and HRP-coupled
anti-biotin antibody (New England Biolabs, Ipswich,
MA).
Cell culture and transient transfections
Rat RINm5F insulinoma cells and HepG2 hepatoma
cells were grown in RPMI 1640 medium with L-gluta-
mine, 10% (v/v) fetal bovine serum, 100 units/ml peni-
cillin, and 100 mg/ml streptomycin at 37°C and 5%
CO2. HIT-T15 hamster insulinoma cells were cultivated
under the same conditions except that 5% horse serum
was added to the medium. Transient transfections were
performed by the polyethyleneimine method (Jet-PEI
reagent; Polyplus-Transfection, Illkirch, France). The
RINm5F cell lines stably expressing WT or mutant
LEPRb have been described previously [43,44]. The dif-
ferent LEPRb constructs have been confirmed to differ
by less than 2.2-fold in their surface expression [44].
Binding assay
RINm5F cells expressing WT LEPRb in 6-well plates
(500,000 cells per well) were serum-starved for 4 h
before they were stimulated with leptin (20 ng/ml). Con-
trol cells were prepared identically but were not treated
with leptin. After 2 h, cells were washed with ice-cold
phosphate buffered saline (PBS) and then with ice-cold
acetic acid (0.5 M NaCl, 0.2 M acetic acid, pH 2.3) to
remove receptor-bound leptin [66]. After three addi-
tional washes with PBS, cell surface expression of
LEPRb was measured using a mouse leptin-secreted
alkaline phosphatase (SEAP) chimeric protein [47].
Bound phosphatase activity was determined by chemo-
luminescence using the CSPD substrate. Nonspecific
binding was determined by incubating parallel cultures
with leptin-SEAP in the presence of an excess of unla-
beled leptin (2 μg/ml). This value was subtracted from
previous total and accounted for ~20% of total binding.
Reporter gene assays
HIT-T15 cells on six-well plates (350.000 cells per well)
were transfected with 0.3 μg of pMET7-LEPRb expres-
sion plasmids [47] along with 0.75 μg each of a STAT3-
responsive luciferase reporter construct containing the
promoter region -215 to +6 of the rat a2 macroglobulin
gene (pGL3a2M-215Luc; [67]) and b-galactosidase
reporter control plasmid pSVb-gal (Promega). HepG2
cells were plated at a density of 150.000/well and were
transfected with 0.15 μg of pMET7-LEPRb. When indi-
cated, variable amounts of expression plasmids pEF-
SOCS1 or pEF-SOCS3 (kindly provided by D. Hilton,
WEHI, Parkville, Australia) or knockdown plasmids for
human SOCS1 (pSM2 vector, target sequence
TGTGGAAAGGACGAAACACC; Openbiosystems
clone v2HS-23987) or SOCS3 (pSUPER-SOCS3, gift of
Fred Schaper, Institute of Biochemistry, Aachen,
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Germany, [68]) were cotransfected. Control wells for
shRNA experiments were cotransfected with empty vec-
tor (pSUPER) or nonsilencing pSM2 construct. Thirty
hours after transfection (54 h in shRNA experiments),
cells were stimulated with 100 ng/ml leptin for 16 h in
serum-free medium. Luciferase activities were deter-
mined from duplicate wells and were normalized to b-
galactosidase activities.
Northern blot analysis
RINm5F-LEPRb cells grown to 80% confluence were
incubated in serum-free medium for 20 h before they
were stimulated with leptin (100 ng/ml) or left unstimu-
lated for variable times. Total RNA was isolated using
the RNeasy Midi Kit (Qiagen, Hilden, Germany), and
samples (10 μg) of total RNA were separated by dena-
turing formaldehyde electrophoresis on 1% (w/v) agar-
ose gels and transferred by capillary blot onto nylon
membranes (Hybond N+; Amersham, Freiburg, Ger-
many). 32P-labeled probes were generated from the
inserts of cDNA clones pEF-SOCS1 and pEF-SOCS3 by
random oligonucleotide priming. Blots were rehybri-
dized with additional cDNA probes following probe
removal with 0.5% SDS at 90-100°C.
Immunoprecipitation and Western blot analysis
For immunoprecipitation of LEPRb receptor complexes,
RINm5F-LEPRb cells from a near-confluent 85-mm
plate were lysed on ice for 30 min in 1 ml of native lysis
buffer (20 mM Tris-HCl pH 7,5; 150 mM NaCl, 1% (v/
v) Brij97, 1 mM EDTA, 10 mM NaF, 1 mM Na3VO4, 1
mM PMSF and 5 μg/ml each of aprotinin and leupep-
tin). Insoluble material was removed by centrifugation
(3 min at 14,000 rpm) before 12 μl of agarose-coupled
c-myc antibody (monoclonal 9E11, Santa Cruz Biotech-
nology) was added to the supernatant and incubated for
4 h at 4°C. For detection of SOCS3, immunoprecipita-
tions were performed with 1% Nonidet P-40 instead of
Brij97 in the lysis buffer and 1 μg of SOCS3 antibody
per 1 ml of lysate. The resin was washed twice with
lysis buffer and twice with lysis buffer without detergent,
and the bound proteins were eluted with denaturing gel
loading buffer.
Total cellular lysates for the detection of STAT3 tyro-
syl phosphorylation were prepared using denaturing
lysis buffer (1% SDS, 20 mM Tris-Cl pH 7.4) and incu-
bation in a boiling water bath for 5 min. For Western
blot analysis, samples were separated by SDS-PAGE (8%
gels), blotted onto nitrocellulose, and positive signals
were revealed by chemiluminescence using the indicated
primary antibodies and horseradish peroxidase- labeled
secondary antibody. Blots were re-probed after removing
the primary antibody by incubating the membrane in
stripping buffer (2% SDS, 50 mM Tris-HCl, 150 mM
NaCl, pH 7.4, 100 mM 2-mercaptoethanol) for 20-30
min at room temperature.
Assay of JAK kinase in LEPRb complexes
LEPRb complexes were immunoprecipitated using agar-
ose coupled c-myc antibody (described above) and
washed twice with kinase buffer (10 mM HEPES pH 7.6,
50 mM NaCl, 5 mM MgCl2, 5 mM MnCl2, 0.4 mM
DTT, 1 mM Na3VO4, 5 μg/ml aprotinin, 5 μg/ml leu-
peptin). For the assay, 2.2 μg of recombinant STAT1
and 28 nmol ATP in 30 μl kinase buffer were added to
the pellets (estimated final concentrations 63 ng/μl
STAT1 and 0.8 mM ATP). After incubation at 30°C for
45 min, supernatants were removed for Western blot
analysis of STAT1 tyrosine phosphorylation. The resin
with the bound receptor complexes was washed twice
with wash buffer (20 mM Tris-HCl pH 7.5, 150 mM
NaCl), eluted, and subjected to Western blot analysis.
Statistical testing
Significance of differences in pairwise comparisons was
analyzed using Student’s t-test. Welch’s t-test was used
in case of unequal variances.
Additional file 1: Supplementary figures. This PDF file contains 2
supplementary figures which show the time course of leptin-induced
STAT3 phosphorylation in HIT-T15 insulinoma cells (Figure S1) and the
inhibitory effect in reporter gene assays and the expression level of
SOCS3 in HIT-T15 cell (Figure S2).
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2091-11-2-
S1.PDF ]
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